|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2004-9-8
|
|
pubmed:abstractText |
We determined the timing of ischemic complications within 30 days after percutaneous coronary intervention (PCI) in patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial. Complications (death, myocardial infarction [MI], target vessel revascularization) occurred in 178 of 2064 patients (8.6%) within 30 days. More than 85% of complications occurred within the 24 hours following randomization, with the greatest risk hazard at 12-18 hours. Unexpectedly, 31% of patients who ultimately met criteria for an endpoint MI within 24 hours of PCI had completely normal CK-MB concentrations at the first 6-hour measurement. There was no rebound increase in events after cessation of eptifibatide. Treatment benefit persisted to 30 days. Post-procedural MI is often not detected until greater than or equal to 12 hours after PCI. Treatment with a glycoprotein IIb/IIIa inhibitor is the only modifiable parameter that reduces the risk for early ischemic complications.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1042-3931
|
|
pubmed:author |
pubmed-author:BlankenshipJames CJC,
pubmed-author:CantorWarren JWJ,
pubmed-author:CrigerDouglas ADA,
pubmed-author:DucasJohnJ,
pubmed-author:GilchristIan CIC,
pubmed-author:KittMichael MMM,
pubmed-author:MadanMinaM,
pubmed-author:O'SheaJ ConorJC,
pubmed-author:PieperKaren SKS,
pubmed-author:SheldonWilliam SWS,
pubmed-author:SmithJack EJE,
pubmed-author:TannenbaumMark AMA,
pubmed-author:TchengJames EJE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
475-81
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15353828-Aged,
pubmed-meshheading:15353828-Angioplasty, Balloon, Coronary,
pubmed-meshheading:15353828-Creatine Kinase,
pubmed-meshheading:15353828-Creatine Kinase, MB Form,
pubmed-meshheading:15353828-Female,
pubmed-meshheading:15353828-Humans,
pubmed-meshheading:15353828-Isoenzymes,
pubmed-meshheading:15353828-Linear Models,
pubmed-meshheading:15353828-Logistic Models,
pubmed-meshheading:15353828-Male,
pubmed-meshheading:15353828-Middle Aged,
pubmed-meshheading:15353828-Myocardial Infarction,
pubmed-meshheading:15353828-Myocardial Ischemia,
pubmed-meshheading:15353828-Peptides,
pubmed-meshheading:15353828-Platelet Aggregation Inhibitors,
pubmed-meshheading:15353828-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:15353828-Postoperative Complications,
pubmed-meshheading:15353828-Risk Factors,
pubmed-meshheading:15353828-Time Factors,
pubmed-meshheading:15353828-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience.
|
|
pubmed:affiliation |
St. Michael's Hospital, Division of Cardiology, 30 Bond Street, Toronto, Ontario, Canada, M44-1W8. cantorw@smh.toronto.on.ca
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
